Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: AbbVie | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: AbbVie

AbbVie and Shire terminate proposed merger

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie

3Q Revenues: $5.0 billion (+8%)

3Q Earnings: $506 million (-48%)

YTD Revenues: $14.5 billion (+6%)

YTD Earnings: $2.6 billion (-14%)

Comments: HUMIRA sales increased 18% to $3.3 billion in the quarter. Kaletra sales were $256 million, up 8%. Synthroid sales were up 24% to $200 million. Creon sales were up 48% to $148 million. Synagis sales were up 12% to $109 million and Duodopa sales were $56 million, up 20%. AndroGel sales were down 7% to $232 million. Dyslipidemia sales were down 77% to $56 million due to loss of exclusivity. On Oct. 20, AbbVie and Shire terminated their proposed merger following AbbVie’s decision to withdraw support for the proposed transaction based on its assessment of a notice issued by the the U.S. Department of Treasury that included changes that negatively impacted the economics of the transaction.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters